The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | The current treatment landscape for SCD
Robert Clark Brown, MD, PhD, Children’s Healthcare of Atlanta, Atlanta, GA, gives an overview of the current treatment landscape for sickle cell disease (SCD), highlighting the use of hydroxyurea and the use of more recently approved therapies including voxelotor, L-glutamine and crizanlizumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Robert Clark Brown, MD, PhD, has participated in consultancy work with Global Blood Therapeutics, Imara and Novo Nordisk; and has received research support from Forma Therapeutics, Global Blood Therapeutics, Imara and Novartis.
